Abstract:Cell death resistance is a hallmark of tumor cells that drives tumorigenesis and drug resistance. Targeting cell death resistance-related genes to sensitize tumor cells and decrease their cell death threshold has attracted attention as a potential antitumor therapeutic strategy. However, the underlying mechanism is not fully understood. Recent studies have reported that NeuroD1, first discovered as a neurodifferentiation factor, is upregulated in various tumor cells and plays a crucial role in tumorigenesis. However, its involvement in tumor cell death resistance remains unknown. Here, we found that NeuroD1 was highly expressed in hepatocellular carcinoma (HCC) cells and was associated with tumor cell death resistance. We revealed that NeuroD1 enhanced HCC cell resistance to ferroptosis, a type of cell death caused by aberrant redox homeostasis that induces lipid peroxide accumulation, leading to increased HCC cell viability. NeuroD1 binds to the promoter of glutathione peroxidase 4 (GPX4), a key reductant that suppresses ferroptosis by reducing lipid peroxide, and activates its transcriptional activity, resulting in decreased lipid peroxide and ferroptosis. Subsequently, we showed that NeuroD1/GPX4-mediated ferroptosis resistance was crucial for HCC cell tumorigenic potential. These findings not only identify NeuroD1 as a regulator of tumor cell ferroptosis resistance but also reveal a novel molecular mechanism underlying the oncogenic function of NeuroD1. Furthermore, our findings suggest the potential of targeting NeuroD1 in antitumor therapy. Aberrant expression of cell death resistance-related genes is common in tumor cells and contributes to their resistance to cell death and tumorigenesis. Transcription factor NeuroD1 has been found to be highly expressed in various tumors and could promote tumorigenesis. However, whether it is involved in tumor cell death resistance remains unclear. In this study, we demonstrate that NeuroD1 enhances the resistance of hepatocellular carcinoma (HCC) cells to ferroptosis. Knocking down NeuroD1 leads to the increase of reactive oxygen species (ROS), toxic lipid peroxides, as well as DNA and mitochondrial damages. These subsequently trigger ferroptosis. We further revealed that NeuroD1 acts as a transcriptional activator of glutathione peroxidase 4 (GPX4), a key molecule that reduces lipid peroxide and thus protects cells against ferroptosis, thereby upregulates the expression level of GPX4 and suppresses HCC cells ferroptosis. Our results also confirmed the critical role of NeuroD1/GPX4 in tumorigenesis in vivo. Together, our findings reveal NeuroD1 as a crucial ferroptosis suppressor gene, thereby unraveling a novel mechanism of tumor cells ferroptosis resistance. Furthermore, our results suggest that targeting NeuroD1 might be a potential antitumor therapeutic strategy.

HECW1 induces NCOA4-regulated ferroptosis in glioma through the ubiquitination and degradation of ZNF350

Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines

FHOD1 is Upregulated in Glioma Cells and Attenuates Ferroptosis of Glioma Cells by Targeting HSPB1 Signaling

Linc01060 suppresses ferroptosis by downregulating SPOP-mediated c-Myc degradation in glioma

NDC80/HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA‐seq and in vitro experiment

Abstract 361: Targeting the suppressor of ferroptosis to improve the treament effeciency of glioblastoma

Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma

The transcription factor HBP1 promotes ferroptosis in tumor cells by regulating the UHRF1-CDO1 axis

Ferroptosis: A novel therapeutic strategy and mechanism of action in glioma

Ferroptosis-related genes with post-transcriptional regulation mechanisms in hepatocellular carcinoma determined by bioinformatics and experimental validation

COPZ1 regulates ferroptosis through NCOA4-mediated ferritinophagy in lung adenocarcinoma

Endothelial cell ferroptosis influences IDH wild-type glioblastoma growth in recurrent glioblastoma multiforme patients

CMTM5 influences Hippo/YAP axis to promote ferroptosis in glioma through regulating WWP2-mediated LATS2 ubiquitination

HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells

O-GlcNAcylation of ZEB1 Facilitated Mesenchymal Pancreatic Cancer Cell Ferroptosis

NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma

Ferroptosis promotes anti-tumor immune response by inducing immunogenic exposure in HNSCC

Heat shock protein 27 deficiency promotes ferrous ion absorption and enhances acyl-Coenzyme A synthetase long-chain family member 4 stability to promote glioblastoma cell ferroptosis

Blockade of GCH1/BH4 Axis Activates Ferritinophagy to Mitigate the Resistance of Colorectal Cancer to Erastin-Induced Ferroptosis

Hsp90 induces Acsl4-dependent glioma ferroptosis via dephosphorylating Ser637 at Drp1

DNA Methylation-Regulated LINC02587 Inhibits Ferroptosis and Promotes the Progression of Glioma Cells Through the CoQ-FSP1 Pathway